期刊
CELL METABOLISM
卷 29, 期 2, 页码 246-253出版社
CELL PRESS
DOI: 10.1016/j.cmet.2019.01.004
关键词
-
资金
- National Institutes of Health [R01DK067158, P01AG051459]
- Robert A. Welch Foundation [I-1558, I-1275]
- Howard Hughes Medical Institute
It has been more than a dozen years since FGF21 burst on the metabolism field in a paper showing that its pharmacologic administration caused weight loss and improved insulin sensitivity and lipoprotein profiles in obese rodents. Since then, FGF21 analogs have advanced all the way to clinical trials, and much progress has been made in understanding FGF21's pharmacology and physiology. In this Perspective, we highlight some of the interesting themes that have emerged from this first dozen years of FGF21 research, including its roles in autocrine/paracrine and endocrine responses to metabolic stress.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据